Henrik Toft Sørensen
- Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registryBy Lie-Ju Hwang, John Teeter, Michael Louie, Henrik Toft Sørensen and Cynthia de LuiseLie-Ju Hwang1Department of Statistics, Specialty Care, Pfizer Inc, New York, NY, United StatesJohn Teeter2Department of Clinical Development and Medical Affairs, Pulmonary Vascular Disease, Pfizer Inc, New York, NY, United StatesMichael Louie2Department of Clinical Development and Medical Affairs, Pulmonary Vascular Disease, Pfizer Inc, New York, NY, United StatesHenrik Toft Sørensen3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, DenmarkCynthia de Luise4Department of Epidemiology, Worldwide Safety Strategy, Pfizer Inc, New York, NY, United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.